Defeating malaria together

Interactive R&D portfolio

MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.

For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full? 

Detailed information is available below (click on the boxes) for translational, development and access projects. This interactive portfolio is updated twice a year, at 1Q and 3Q. 


Legend

* Pending review or approval by WHO prequalification, or by regulatory bodies who are ICH members or observers


 Brought into portfolio after approval; collaboration with DNDi.

1 First approval: Novartis (brand name: Coartem® Dispersible). Generics by Ajanta, Cipla, Ipca, Strides, Macleods, Mylan
2 Brand name: Artesun® 
3 Brand name: Eurartesim®
4 Brand name: Pyramax® tablets and granules
5 First approval fixed-dose combination: Sanofi/DNDi (brand name: ASAQ Winthrop®). Generics by Ajanta, Cipla, Guilin, Ipca, Strides.  
6 Brand name: SPAQ-COTM

Target Product Profiles - represented by coloured bar(s) under the project box

____  3-day cure artemisinin-based combination therapies

____  New compounds to contribute to SERCAP or multiple exposure treatment for multi-drug resistance

____  Severe malaria

____  Seasonal malaria chemoprevention

____  Relapse prevention

Target Candidate Profiles- represented by icons


 Asexual blood stage activity


 Relapse prevention


 Transmission reduction (gametocytocidal or sporontocidal)


 Chemoprevention